|
|
Management
BG Medicine has assembled a world-class team of managers who each bring distinct industry and technology experience, a history of success, and a passion to succeed to their leadership roles. - Pieter Muntendam, MD
- President and CEO
- C. Douglas White,
- Executive Vice President and General Manager, Diagnostics
- Neal Gordon, Ph.D.,
- Senior Vice President, Biomarker Discovery
- Carol A. Adiletto, M.S.
- Vice President, Clinical and Regulatory Affairs
- Dr. Peter Gardiner
- Vice President, Medical Affairs & Chief Medical Officer
- Aram Adourian, PhD
- Vice President, Scientific Affairs
- Gregg Mayer
- Vice President, Diagnostic Strategy
- Rene Myers, PhD
- Vice President, Strategic Alliances
- Stacie Rader
- Vice President, Human Resources
Pieter Muntendam, MD
President and CEO
Pieter Muntendam, MD, is a bio-pharmaceutical and healthcare executive with 20 years of business experience ranging from multinational corporations to early stage enterprises. He received his MD from Leiden University in The Netherlands, where he began his career with Organon International and went on to hold key roles in some of the world’s largest pharmaceutical firms. As Vice President of Care Management at Glaxo Wellcome (now GlaxoSmithKline), Dr. Muntendam was responsible for the development and implementation of its entry strategy within the field of care and disease management. Previously he was Vice President of Research and Development, International, and a member of the Board of Directors for two Johnson & Johnson operating companies. Most recently he led the Bio-Pharmaceutical and Healthcare practice at NetNumina, a professional services company focused on leveraging information technology to improve biopharma yield and efficiency. Dr. Muntendam’s extensive experience with early stage companies includes founding health management firm ProMedex, acquired by SHPS in 2004; and co-founding a subsidiary of Millennium Pharmaceuticals, Vitivity, where he served as Vice President of Medicine.
back to top
C. Douglas White
Executive Vice President and General Manager, Diagnostics
Mr. White has 24 years of experience in the IVD market serving multiple senior executive roles . He has a successful track record in the leadership and development of markets and commercial organizations at Digene, Bayer and Chiron Diagnostics. Most recently Mr. White was Sr. VP of Sales and Marketing, Americas and Chair of the Americas Management Counsel at QIAGEN. In his role at QIAGEN he was part of the executive leadership team responsible for the successful integration of Digene Corporation into QIAGEN. At Digene, Mr. White served as the Sr. Vice President of Commercial Operations where he was responsible for all commercial activities in the Americas and Asia Pacific in addition to the global product management organization. Prior to joining Digene, Mr. White held several executive positions in the diagnostic industry, including, Vice President of US Sales and Marketing as well as Vice President of Global Product Management, Nucleic Acid Diagnostics at Bayer Diagnostics. He was Vice President, Marketing for Chiron Diagnostics and served in several different management roles in sales, market development, strategic and tactical marketing through his career at Chiron and Abbott Diagnostics. Mr.White has a B.A. in Political Science from Washington College.
back to top
Neal Gordon, Ph.D.
Senior Vice President, Biomarker Discovery
Dr. Gordon is a veteran of 20 years in the biotechnology industry serving both as a senior executive and in product development. From 2004-2008, Dr. Gordon was President of Epitome Biosystems, where he spearheaded the development and subsequent market introduction of an innovate line of multiplexed protein immunoassay products leading to the sale of the company to Millipore in January 2009. From 1998 to 2004, Dr. Gordon was at Antigenics Inc, first as Vice President of Process Development and then as Senior Vice President of Manufacturing Operations. Dr. Gordon joined Antigenics in 1998, following 10 years at PerSeptive Biosystems, now part of Life Technologies (Applied Biosystems/Invitrogen merger). As part of the founding technology team, he led the development, application and market launch of innovative technologies for the purification and analysis of proteins, including the BIOCAD perfusion chromatography workstation. Earlier he was a product development engineer at Proctor & Gamble. Dr. Gordon obtained a Bachelors Degree in chemical engineering from McGill University, and a Ph.D. in biochemical engineering from Massachusetts Institute of Technology.
back to top
Carol A. Adiletto, M.S.
Vice President, Clinical and Regulatory Affairs
Ms. Adiletto has 25 years of experience in the medical industry with extensive experience in the in vitro diagnostics (IVD) field in multiple research, product development, clinical, and regulatory roles. Prior to joining BG Medicine Ms. Adiletto was the Sr. Vice President, Clinical & Regulatory Affairs at WorldCare Clinical, LLC. Ms. Adiletto held senior executive roles including World Wide Vice President Clinical and Regulatory Affairs for the Cardiac Marker Division of Inverness Medical Innovations, Inc. In addition, Ms. Adiletto held senior level clinical and regulatory positions with Inverness Medical Technology where she successfully led the activities for market approval of multiple OTC, POC and professional-use IVD products. Ms. Adiletto served as Director of Clinical Affairs at LifeScan, Inc. after Johnson & Johnson acquired Inverness Medical for $1.3b in 2001. Ms. Adiletto started her career at Instrumentation Laboratory in the fields of clinical chemistry research, product development and experimental design/statistics. Ms. Adiletto has a B.S. in Medical Laboratory Science and M.S. with Clinical Chemistry Specialization from Northeastern University.
back to top
Dr. Peter Gardiner
Vice President, Medical Affairs & Chief Medical Officer
Peter brings 25 years of successful experience in the pharmaceutical and medical device industries to BG Medicine. He has held senior roles with DuPont’s Medical Imaging business, Gensia, Inc., GD Searle & Co. Prior to joining BG Medicine, he has served as Medical Director, Global Medical Affairs & Senior Medical Officer for Bristol-Myers Squibb (BMS) Medical Imaging and Vice President, Medical Sciences for the Medical Imaging division. After obtaining his medical degree from Leeds University in the UK, Peter trained in internal medicine and cardiology. Peter is a member of the Royal College of Physicians, United Kingdom, and of the Faculty of Pharmaceutical Medicine.
back to top
Stacie Rader
Vice President, Human Resources
Prior to joining BG Medicine, Ms. Rader was Vice President at Flagship Ventures and Vice President, Human Resources, of NewcoGen since 1999. During her tenure with Flagship she has consulted with numerous portfolio entities on HR operational issues. Stacie has particular expertise in team building, staffing, and organizational development as well as compensation and benefits design and implementation. Prior to Flagship Ventures, she was Corporate Director of Worldwide Employment and Staffing for Applera Corporation (now Applied Biosystems) following the merger of Perkin Elmer and PerSeptive Biosystems in 1998. Stacie was responsible for all Human Resources functions at PerSeptive from 1992 to 1998. During this period, she oversaw the hiring of 600 global employees and the implementation of core HR processes and programs as well as equity and compensation structures to accommodate the company’s rapid growth. She was also a key member of corporate due diligence teams for a number of PerSeptive acquisitions and was instrumental in the integration and assimilation process for the PE-PerSeptive merger and held an interim VP, Human Resources role at Celera Genomics. Stacie holds a B.S. from Babson College.
back to top
Aram Adourian, PhD
Vice President, Scientific Affairs
Dr. Adourian joined BG Medicine from the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology. While at MIT, he served as Project Manager for Bioinformatics specializing in the development of novel systems and approaches for biomolecular sequencing, analysis and modeling. Dr. Adourian earned his PhD at Harvard University in Statistical Physics, where he was a recipient of the Rudenberg Research Prize, and received his undergraduate degree in Physics from Cornell University.
back to top
Rene Myers, PhD
Vice President, Strategic Alliances
Dr. Myers came to BG Medicine from Biotage AB (formerly Pyrosequencing) where she was Vice President, Technology and Support. Rene held both scientific and business development roles during her tenure at Biotage and played an integral role in identifying and fostering strategic relationships at key accounts and developing new sales channels into targeted clinical research. Prior, Rene was with Applied Biosystems as a managing scientist on the PNA Research and Development team, Schleicher and Schuell,Inc. as a managing Sr. Scientist and Verigen Inc. She received her Ph.D. from the Ohio State University and a BS from Heidelberg College.
back to top
Gregg Mayer
Vice President, Diagnostic Strategy
Mr. Mayer joined BG Medicine in May 2007, bringing over 20 years experience as a lifescience executive at leading medical products companies. Most recently, Mr. Mayer was Chief Business Officer at Interleukin Genetics, a developer of specialty genetic tests. Prior to Interleukin, Mr. Mayer was Vice President, Strategic Marketing and Corporate Communications at EPIX Pharmaceuticals, an innovator in magnetic resonance imaging contrast agents, where he managed the company's lead product development program. During his EPIX tenure, Mr. Mayer was elected Chairman of the Medical Imaging Contrast Agent Association and led industry initiatives on U.S. regulatory and reimbursement policy. Before EPIX, Mr. Mayer was Worldwide Marketing Manager, Immunodiagnostics at Chiron Diagnostics (now part of Siemens Medical Solutions Diagnostics) where he planned and managed the development and global launch of more than 30 in vitro diagnostic products in reproductive endocrinology, cardiovascular disease, thyroid function, and other disease areas. He was subsequently U.S. Director of Marketing at Chiron and was responsible for the development and execution of commercial strategy for new immunodiagnostic assays and laboratory systems. Mr. Mayer began his career in sales with Abbott Diagnostics, and eventually joined Abbott's TDx Business Unit where he led portfolio strategy for in vitro transplant immunosuppression and therapeutic drug monitoring diagnostic products. Mr. Mayer holds an MBA from Northwestern University's Kellogg Graduate School of Management and a BBA from The University of Texas at Austin.
back to top
|
